Doppler ultrasound is a noninvasive modality for portal hemodynamic study. However, inter-observer variability has been observed. This study has investigated ways to produce less inter-observer variability. Doppler ultrasound portal vein hemodynamic studies were carried out by three well-trained specialists on 20 healthy hospital staff members. The intra-hepatic, first branch, right portal vein, the hilar portal vein, and the extra-hepatic portal vein were chosen for study. With respect to the diameter of portal veins, a significant inter-observer variability was found for the first branch right portal vein and the extra-hepatic portal vein, but not for the hilar portal vein. For maximal portal vein velocity studies, inter-observer variability was not found at any location. A significant failure rate was noted for the measurement of extra-hepatic portal vein velocity. Only 8 volunteers had complete data from all of the three investigators. A significant variability was also noted for the average velocity of extra-hepatic portal vein. We conclude that Doppler ultrasound hemodynamic studies of the hilar portal vein has the most acceptable inter-observer variability and thus should be used for longitudinal portal hemodynamic studies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/(SICI)1097-0096(199602)24:2<61::AID-JCU2>3.0.CO;2-I | DOI Listing |
J Vet Intern Med
January 2025
Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA.
Background: Dogs with hepatocutaneous syndrome (HCS) have marked plasma hypoaminoacidemia, but its occurrence in dogs with chronic liver diseases not associated with HCS (non-HCS CLD) is unknown.
Objectives: To determine if plasma hypoaminoacidemia occurs in dogs with non-HCS CLD, compare plasma amino acid (PAA) profiles between dogs with non-HCS CLD and HCS, and define a sensitive and specific PAA pattern for diagnosing HCS.
Animals: Data were collected from client-owned dogs, a prospective cohort of 32 with CLD and 1 with HCS, and a retrospective cohort of 7 with HCS.
Front Immunol
January 2025
Department of Rheumatology and Immunology, the Second Affiliated Hospital of Xiamen Medical College, Xiamen, China.
Introduction: Systemic lupus erythematosus (SLE) complicated by thrombotic microangiopathy (TMA) and non-cirrhotic portal hypertension (NCPH) is rare. We present a case of a female patient with SLE who developed TMA and NCPH and responded positively to rituximab and plasma exchange treatment.
Case Description: A 53-year-old woman was admitted with 6 h of confusion.
J Hepatocell Carcinoma
January 2025
Department of Interventional and Vascular Surgery, Peking University First Hospital, Beijing, People's Republic of China.
Purpose: Portal vein tumor thrombus (PVTT)-related severe symptomatic portal hypertension (SPH) leads to a poor prognosis in patients with advanced hepatocellular carcinoma (HCC). Traditional transjugular intrahepatic portosystemic shunt (TIPS) using covered plus bare stent can effectively relieve SPH, however, the bare segment is susceptible to obstruction due to PVTT invasion. This study aimed to evaluate the safety and efficacy of fully covered stent-TIPS (FCS-TIPS) for treatment of PVTT-related SPH in advanced HCC patients.
View Article and Find Full Text PDFJ Pak Med Assoc
January 2025
Department of Nuclear Medicine, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.
"Hot quadrate lobe sign" refers to visualization of caudate lobe of liver due to excess accumulation of radiotracer secondary to superior vena cava obstruction. Collateral channels are formed between thoracic and mediastinal vessels; internal mammary through the paraumbilical vessels which drain blood to the left portal vein and into the caudate lobe of liver. It was first described on Tc99-m sulfur colloid scan.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Centro Hospitalar e Universitario de Coimbra EPE, Coimbra, Portugal.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!